retatrutide clinical trial phase retatrutide Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide, a TRIPLE agonist (GLP1,

Dose escalation is critical for tolerability GI side effects are dose-dependent

Notably, nearly 50% of the retatrutide phase 2 obesity trial were men, which is higher than in phase 3 clinical trials with tirzepatide (32.5% in SURMOUNT-1 [27]) and semaglutide 2.4 mg (25.9% in STEP-1 [8])

A common practice for a 30 mg vial is to add 3 mL of BAC water

Understanding GLP-1 GLP-1 is a naturally occurring hormone released by the intestines after eating

FAQ : Product registration

I think there are many people who are using it as a marketing tool because they want people to think youre not on a full dose of a GLP-1, she says